Literature DB >> 15056427

[Retrospective study of patients who undergo pacemaker implantation in short-stay ambulatory surgery. Long-term follow-up and cost analysis].

Sergio Villalba1, José Roda, Aurelio Quesada, Víctor Palanca, Cristóbal Zaragoza, Ernesto Bataller, José A Velasco.   

Abstract

INTRODUCTION AND
OBJECTIVES: The aim of this study was to analyze data concerning mortality, morbidity, the number of re-admissions, complications, and cost per patient after pacemaker implantation, in groups of patients with different postoperative follow-up regimens. PATIENTS AND
METHOD: Data from 2108 patients with definitive pacemakers implanted between January, 1991 and December, 2001 were analyzed retrospectively. We took into account the length of hospital stay and pacemaker dependence: group I, non-pacemaker dependent ambulatory patients with no hospital admission (NPMD) (n=710); group II, pacemaker-dependent patients with a short hospital stay of up to 48 hours (PMD) (n=779); group III, non-pacemaker-dependent patients with routine hospitalization for more than 48 hours (NPMD) (n=289); and group IV, pacemaker-dependent patients with routine hospitalization for more than 48 hours (PMD) (n=330).
RESULTS: Total mortality was 3.9% (n=83), and no deaths were directly related to surgery. The cause of death was cardiac in 1.4% (n=30), non-cardiac in 2.3% (n=49), and unknown in 0.2% (n=4) of the patients. Mortality was premature (<30 days) in 38 patients (1.8%) and non-premature (>30 days) in 45 patients (2.1%). Total mortality was the same in Groups I and II (0.2%), and morbidity was 0.75%, and 0.9%, respectively. There were no premature deaths in these first 2 groups. In groups III and IV, mortality rose to 1.5% and 2% and morbidity to 0.9% and 1%. The total number of re-admissions (premature and non-premature) was higher in Groups III (6 re-admissions) and IV (9 re-admissions). The average total cost per patient, considering the sum of the average unit costs of the activities in each one of the medical processes which were studied (i.e., hospitalization, home visits, surgical activity, re-admissions, and second operations) was 117 euros in group I (ambulatory surgery) and 280 euros in group II (short stay). In both groups III and IV (hospitalization) the average total cost rose to 917.80 euros.
CONCLUSIONS: Major ambulatory surgery may be an economical and efficient procedure for the health care system if it is used in carefully screened patients with cardiac stimulation.

Entities:  

Mesh:

Year:  2004        PMID: 15056427

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  5 in total

Review 1.  [Strategies for the avoidance and treatment of complications during pacemaker implantation].

Authors:  C Kolb
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-12

2.  Implantation of a cardiac pacemaker - comparison of subjective stress and mood between in- and outpatients.

Authors:  Jacqueline Müller-Nordhorn; Gudrun Schüler; Stephanie Roll; Stefan N Willich
Journal:  Clin Res Cardiol       Date:  2006-08-16       Impact factor: 5.460

Review 3.  Pacemaker implantation in small hospitals: complication rates comparable to larger centres.

Authors:  Bjørn Haug; Kjærsti Kjelsberg; Knut Tore Lappegård
Journal:  Europace       Date:  2011-06-28       Impact factor: 5.214

4.  A methodology to estimate the potential to move inpatient to one day surgery.

Authors:  Nicolas Gilliard; Yves Eggli; Patricia Halfon
Journal:  BMC Health Serv Res       Date:  2006-06-19       Impact factor: 2.655

5.  Safety of same-day discharge versus overnight stay strategy following cardiac device implantations: a high-volume single-centre experience.

Authors:  Stefanos Archontakis; Evangelos K Oikonomou; Konstantinos Sideris; Ageliki Laina; Dimitra Tirovola; Dimitra Paraskevopoulou; Panagiotis Kostakis; Ioannis Doundoulakis; Petros Arsenos; Ioannis Ntalakouras; Emmanouil Charitakis; Konstantinos Gatzoulis; Konstantinos Tsioufis; Skevos Sideris
Journal:  J Interv Card Electrophysiol       Date:  2022-09-05       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.